Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.71 |
| ▸ | MRE11 | P49959 | 1/20 | 0.71 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | XDH | P47989 | 3/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.55 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK3 | P49761 | 1/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 6/20 | 0.53 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.53 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | GSK3B | P49841 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8185407 | 1.00 | MEN1 (0.71) | MEN1KMT2AMRE11POLBXDH | |
| SCHEMBL8001437 | 0.86 | AKR1B1 (0.71) | AKR1B1PIM1PIM2PIM3HPGD | |
| SCHEMBL8001434 | 0.86 | AKR1B1 (0.71) | AKR1B1PIM1PIM2PIM3HPGD | |
| SCHEMBL15332601 | 0.85 | MEN1 (0.73) | MEN1KMT2AMRE11POLBXDH | |
| SCHEMBL15332599 | 0.85 | MEN1 (0.73) | MEN1KMT2AMRE11POLBXDH | |
| Mirin SCHEMBL21296287 | 0.83 | MRE11 (1.00) | MEN1KMT2AMRE11POLBXDH | |
| Mirin SCHEMBL15421605 | 0.83 | MRE11 (1.00) | MEN1KMT2AMRE11POLBXDH | |
| Mirin SCHEMBL15421606 | 0.83 | MRE11 (1.00) | MEN1KMT2AMRE11POLBXDH | |
| SCHEMBL22971852 | 0.83 | XDH (0.75) | MEN1KMT2AMRE11POLBXDH | |
| SCHEMBL23094478 | 0.80 | CISD1 (0.73) | MEN1KMT2AMRE11POLBXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025233535-A1 | METHOD FOR THE DETERMINATION OF CLEAVAGE SITES IN GENOMIC DNA CAUSED BY EXPOSURE TO A SITE DIRECTED NUCLEASE | ETH Zürich (CH) | 2025-11-13 | — | — | WO | claimed |
| US-20250043258-A1 | CRISPR-based DNA Repair-Inhibiting Intratumoral Cancer Therapy | RNA Therapeutics, Inc. (US) | 2025-02-06 | — | — | US | claimed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | claimed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | claimed |
| WO-2025233535-A1 | METHOD FOR THE DETERMINATION OF CLEAVAGE SITES IN GENOMIC DNA CAUSED BY EXPOSURE TO A SITE DIRECTED NUCLEASE | ETH Zürich (CH) | 2025-11-13 | — | — | WO | disclosed |
| US-20250043258-A1 | CRISPR-based DNA Repair-Inhibiting Intratumoral Cancer Therapy | RNA Therapeutics, Inc. (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240336622-A1 | NIMBOLIDE ANALOGS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-10-10 | — | — | US | disclosed |
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-16 | — | — | US | disclosed |
| EP-4274564-A1 | NIMBOLIDE ANALOGS AND METHODS OF USE THEREOF | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-15 | — | — | EP | disclosed |
| CN-117042765-A | Azadirachtin analogs and methods of use thereof | 德克萨斯大学系统董事会 | 2023-11-10 | — | — | CN | disclosed |
| US-20230332256-A1 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | UNIV JOHNS HOPKINS (US) | 2023-10-19 | — | — | US | disclosed |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | CITY OF HOPE (US) | 2023-10-10 | — | — | US | disclosed |
| EP-4213948-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | Board of Regents, The University of Texas System (US) | 2023-07-26 | — | — | EP | disclosed |
| WO-2022060477-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-03-24 | — | — | WO | disclosed |
| WO-2022061172-A2 | NUCLEIC ACID DETECTION USING A NUCLEASE ACTUATOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-24 | — | — | WO | disclosed |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2022-02-17 | — | — | US | disclosed |
| WO-2000018746-A1 | THIAZOLIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230366033-A1 | METHODS FOR TREATING CANCERS WITH INHIBITORS TARGETING THE ROLE OF GRB2 IN DNA REPAIR | GRB2, RAD51, MRE11 | MEN1 3237/4885KMT2A 995/4885MRE11 3/4885 |
| US-20240336622-A1 | NIMBOLIDE ANALOGS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | MEN1 2145/4885KMT2A 1063/4885MRE11 153/4885 |
| US-20220048863-A1 | DNA2 INHIBITORS FOR CANCER TREATMENT | DNA2, TOP2A, TOP2B | MEN1 3911/4885KMT2A 470/4885MRE11 58/4885 |
| US-11780815-B2 | DNA2 inhibitors for cancer treatment | DNA2, TOP2A, TOP2B | MEN1 3911/4885KMT2A 470/4885MRE11 58/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.